September 2017 | Targeted Therapies in Oncology

Debating the True Benefit of Adjuvant TKIs in High-Risk RCC

September 21, 2017

Clinical Articles

Adjuvant therapy with TKIs for patients with high-risk renal cell carcinoma who have undergone a nephrectomy may be supported by level IIa evidence from the National Comprehensive Cancer Network guidelines, yet this approach is still controversial, with many physicians believing that there are not yet enough data in support of its use.